uniQure NVMEX:QUREN 29 EBITDA Margin % is -1,012.36% as of Mar. 2026. GuruFocus rates MEX:QUREN with a GF Score™ of 29/100 and a GF Value™ of MXN99.43 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, uniQure NV ranks worse than 76.27% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. uniQure NV's EBITDA for the
three
months ended in Mar. 2026 was MXN-650.3 Mil. uniQure NV's Revenue for the
three
months ended in Mar. 2026 was MXN64.2 Mil. Therefore, uniQure NV's EBITDA margin for the quarter that ended in Mar. 2026 was -1,012.36%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
uniQure NV EBITDA Margin % Related Terms
uniQure NV EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for uniQure NV's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:QUREN vs NVAX, HRMY, IOVA: EBITDA Margin % Comparison
For the Biotechnology subindustry, uniQure NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
uniQure NV EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, uniQure NV's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where uniQure NV's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
uniQure NV (MEX:QUREN) has a EBITDA Margin % of -1,012.36% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on uniQure NV and its competitors. According to the industry distribution chart, uniQure NV ranks #720 out of 944 companies in the Biotechnology industry, placing it in the top 76.3%.
Is uniQure NV's EBITDA Margin % too high?
uniQure NV's current EBITDA Margin % is -1,012.36%. Based on the distribution chart, uniQure NV ranks #720 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, uniQure NV has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's EBITDA Margin % compare to NVAX and HRMY?
According to the Biotechnology industry distribution chart, uniQure NV ranks #720 out of 944 companies for EBITDA Margin %. This places uniQure NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on uniQure NV and its competitors. uniQure NV's current EBITDA Margin % is -1,012.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (MEX:QUREN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN99.43, compared to a current price of MXN795.45 — trading 700% above its estimated fair value. The current EBITDA Margin % is -1,012.36%. uniQure NV's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For uniQure NV (MEX:QUREN), the current EBITDA Margin % is -1,012.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is uniQure NV (MEX:QUREN) Overvalued in 2026?
Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued.
The current stock price of MXN795.45 is trading 700% above its estimated GF Value™ of MXN99.43.
GuruFocus considers uniQure NV to be Significantly Overvalued.
Key valuation signals for MEX:QUREN:
EBITDA Margin %: -1,012.36%
GF Value™: MXN99.43 vs. price of MXN795.45 (700% above fair value)
No single metric tells the full story. See the MEX:QUREN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
29GF Score
Get the complete analysis for MEX:QUREN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:QUREN has been successfully added to your 
